Investment analysts at BTIG Research initiated coverage on shares of NuVasive, Inc. (NASDAQ:NUVA) in a research report issued on Thursday. The brokerage set a “buy” rating and a $82.00 price target on the medical device company’s stock. BTIG Research’s price target would suggest a potential upside of 33.55% from the stock’s previous close.

A number of other research firms have also recently weighed in on NUVA. Cowen and Company reaffirmed an “outperform” rating and set a $90.00 price target (up previously from $85.00) on shares of NuVasive in a report on Wednesday, June 28th. Robert W. Baird cut NuVasive from an “outperform” rating to a “neutral” rating and cut their price target for the company from $79.00 to $72.00 in a report on Friday, July 28th. Gabelli reissued a “buy” rating on shares of NuVasive in a report on Monday, July 31st. Royal Bank Of Canada reissued a “buy” rating and set a $85.00 target price on shares of NuVasive in a report on Thursday, July 20th. Finally, Zacks Investment Research cut NuVasive from a “buy” rating to a “hold” rating in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the company’s stock. NuVasive currently has an average rating of “Buy” and an average price target of $81.25.

NuVasive (NASDAQ NUVA) opened at 61.40 on Thursday. NuVasive has a 52-week low of $56.70 and a 52-week high of $81.68. The firm’s 50-day moving average price is $66.12 and its 200 day moving average price is $72.86. The firm has a market cap of $3.12 billion, a PE ratio of 96.69 and a beta of 1.08.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.02. The company had revenue of $260.60 million for the quarter, compared to analysts’ expectations of $261.95 million. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 earnings per share. On average, equities analysts anticipate that NuVasive will post $2.00 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “NuVasive, Inc. (NUVA) Now Covered by BTIG Research” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/09/nuvasive-inc-nuva-now-covered-by-btig-research.html.

In other NuVasive news, CEO Gregory T. Lucier purchased 2,000 shares of the firm’s stock in a transaction on Tuesday, August 29th. The shares were purchased at an average price of $61.52 per share, for a total transaction of $123,040.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Peter Michael Leddy purchased 7,850 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was acquired at an average price of $63.88 per share, for a total transaction of $501,458.00. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 14,850 shares of company stock worth $955,598. 1.20% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of NUVA. Koch Industries Inc. grew its position in NuVasive by 26,406.7% during the 2nd quarter. Koch Industries Inc. now owns 982,337 shares of the medical device company’s stock worth $970,000 after purchasing an additional 978,631 shares in the last quarter. Voya Investment Management LLC grew its position in NuVasive by 43.7% during the 2nd quarter. Voya Investment Management LLC now owns 1,699,964 shares of the medical device company’s stock worth $130,761,000 after purchasing an additional 517,115 shares in the last quarter. OppenheimerFunds Inc. grew its position in NuVasive by 55.8% during the 1st quarter. OppenheimerFunds Inc. now owns 1,210,999 shares of the medical device company’s stock worth $90,438,000 after purchasing an additional 433,506 shares in the last quarter. TIAA CREF Investment Management LLC grew its position in NuVasive by 118.7% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 546,740 shares of the medical device company’s stock worth $42,055,000 after purchasing an additional 296,715 shares in the last quarter. Finally, Victory Capital Management Inc. grew its position in NuVasive by 70.8% during the 1st quarter. Victory Capital Management Inc. now owns 715,321 shares of the medical device company’s stock worth $53,420,000 after purchasing an additional 296,568 shares in the last quarter.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Stock Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related stocks with our FREE daily email newsletter.